{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:48:29Z","timestamp":1781650109857,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s42000-023-00437-7","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:02:47Z","timestamp":1677081767000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves\u2019 disease: a cross-sectional study"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5250-8138","authenticated-orcid":false,"given":"Masahito","family":"Katahira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tsunekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahori","family":"Tsuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"437_CR1","first-page":"353","volume-title":"Werner & Ingbar\u2019s the thyroid: a fundamental and clinical text","author":"TF Davis","year":"2021","unstructured":"Davis TF, Tomer Y (2021) Thyroid diseases: thyrotoxicosis. In: Braverman LE, Cooper DS, Kopp PA (eds) Werner & Ingbar\u2019s the thyroid: a fundamental and clinical text, 11th edn. Wolters Kluwer, Philadelphia, pp 353\u2013369","edition":"11"},{"key":"437_CR2","first-page":"267","volume-title":"Werner & Ingbar\u2019s the thyroid: a fundamental and clinical text","author":"U Feldt-Rasmussen","year":"2021","unstructured":"Feldt-Rasmussen U (2021) Laboratory measurement of thyroid-related hormones, proteins, and autoantibodies in serum. In: Braverman LE, Cooper DS, Kopp PA (eds) Werner & Ingbar\u2019s the thyroid: a fundamental and clinical text, 11th edn. Wolters Kluwer, Philadelphia, pp 267\u2013299","edition":"11"},{"key":"437_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fimmu.2017.00521","volume":"8","author":"E Fr\u00f6hlich","year":"2017","unstructured":"Fr\u00f6hlich E, Wahl R (2017) Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Front Immunol 8:521","journal-title":"Front Immunol"},{"key":"437_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF03348328","volume":"5","author":"S Mariotti","year":"1982","unstructured":"Mariotti S, Pisani S, Russova A, Pinchera A (1982) A new solid-phase immunoradiometric assay for anti-thyroglobulin autoantibody. J Endocrinol Invest 5:227\u2013233","journal-title":"J Endocrinol Invest"},{"key":"437_CR5","unstructured":"Japan Thyroid Association (2010) Guidelines for the Diagnosis of Graves\u2019 Disease.\u00a0Nankodo Co., Ltd.\u00a0Tokyo.\u00a0http:\/\/www.japanthyroid.jp\/en\/guidelines.html#Gra. Accessed 19 Mar\u00a02022"},{"key":"437_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.diabres.2009.06.007","volume":"85","author":"M Katahira","year":"2009","unstructured":"Katahira M, Maeda H, Tosaki T, Segawa S (2009) The human leukocyte antigen class II gene has different contributions to autoimmune type 1 diabetes with or without autoimmune thyroid disease in the Japanese population. Diabetes Res Clin Pract 85:293\u2013297","journal-title":"Diabetes Res Clin Pract"},{"key":"437_CR7","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1210\/jc.2018-00509","volume":"103","author":"T Diana","year":"2018","unstructured":"Diana T, Daiber A, Oelze M, Neumann S, Olivo PD, Kanitz M et al (2018) Stimulatory TSH-Receptor Antibodies and Oxidative Stress in Graves Disease. J Clin Endocrinol Metab 103:3668\u20133677","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s12020-014-0399-3","volume":"48","author":"H Baser","year":"2015","unstructured":"Baser H, Can U, Baser S, Yerlikaya FH, Aslan U, Hidayetoglu BT (2015) Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. Endocrine 48:916\u2013923","journal-title":"Endocrine"},{"key":"437_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-15-0617","volume":"173","author":"I Ates","year":"2015","unstructured":"Ates I, Yilmaz FM, Altay M, Yilmaz N, Berker D, G\u00fcler S (2015) The relationship between oxidative stress and autoimmunity in Hashimoto\u2019s thyroiditis. Eur J Endocrinol 173:791\u2013799","journal-title":"Eur J Endocrinol"},{"key":"437_CR10","first-page":"83","volume":"34","author":"J Sewerynek","year":"2000","unstructured":"Sewerynek J, Wiktorska J, Nowak D, Lewinski A (2000) Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease. Endocr Regul 34:83\u201389","journal-title":"Endocr Regul"},{"key":"437_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1055\/s-2007-957347","volume":"39","author":"M Schott","year":"2007","unstructured":"Schott M, Eckstein A, Willenberg HS, Nguyen TB, Morgenthaler NG, Scherbaum WA (2007) Improved prediction of relapse of Graves\u2019 thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies. Horm Metab Res 39:56\u201361","journal-title":"Horm Metab Res"},{"key":"437_CR12","first-page":"328","volume":"114","author":"N Hamada","year":"1987","unstructured":"Hamada N, Ito K, Mimura T, Ishikawa N, Momotani N, Noh J et al (1987) Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves\u2019 disease. Acta Endocrinol (Copenh) 114:328\u2013335","journal-title":"Acta Endocrinol (Copenh)"},{"key":"437_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1210\/jcem-57-3-563","volume":"57","author":"JH Romaldini","year":"1983","unstructured":"Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC et al (1983) Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 57:563\u2013570","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1089\/thy.2006.16.1041","volume":"16","author":"I Guilhem","year":"2006","unstructured":"Guilhem I, Massart C, Poirier JY, Maugendre D (2006) Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves\u2019 disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal. Thyroid 16:1041\u20131045","journal-title":"Thyroid"},{"key":"437_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40618-013-0026-9","volume":"37","author":"M Stefanic","year":"2014","unstructured":"Stefanic M, Karner I (2014) Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves\u2019 disease in Croatian patients. J Endocrinol Invest 37:71\u201377","journal-title":"J Endocrinol Invest"},{"key":"437_CR16","doi-asserted-by":"publisher","first-page":"E1466","DOI":"10.1210\/jc.2011-0228","volume":"96","author":"S Hutfless","year":"2011","unstructured":"Hutfless S, Matos P, Talor MV, Caturegli P, Rose NR (2011) Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab 96:E1466\u2013E1471","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000495504","volume":"8","author":"O Lindgren","year":"2019","unstructured":"Lindgren O, Asp P, Sundl\u00f6v A, Tennvall J, Shahida B, Planck T et al (2019) The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves\u2019 Disease. Eur Thyroid J 8:64\u201369","journal-title":"Eur Thyroid J"},{"key":"437_CR18","first-page":"411","volume":"123","author":"Y Yamaguchi","year":"1990","unstructured":"Yamaguchi Y, Inukai T, Iwashita A, Nishino M, Yamaguchi T, Shohda Y et al (1990) Changes in thyroid volume during antithyroid drug therapy for Graves\u2019 disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin. Acta Endocrinol (Copenh) 123:411\u2013415","journal-title":"Acta Endocrinol (Copenh)"},{"key":"437_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/eje.0.1310125","volume":"131","author":"SW Kuo","year":"1994","unstructured":"Kuo SW, Huang WS, Hu CA, Liao WK, Fung TC, Wu SY (1994) Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves\u2019 hyperthyroidism during antithyroid drug therapy. Eur J Endocrinol 131:125\u2013130","journal-title":"Eur J Endocrinol"},{"key":"437_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/0002-9343(90)90435-G","volume":"88","author":"RN Bitton","year":"1990","unstructured":"Bitton RN, Wexler C (1990) Free triiodothyronine toxicosis: a distinct entity. Am J Med 88:531\u2013533","journal-title":"Am J Med"},{"key":"437_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0002-9343(94)90147-3","volume":"96","author":"J Figge","year":"1994","unstructured":"Figge J, Leinung M, Goodman AD, Izquierdo R, Mydosh T, Gates S (1994) The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med 96:229\u2013234","journal-title":"Am J Med"},{"key":"437_CR22","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s40618-021-01505-8","volume":"44","author":"S Khamisi","year":"2021","unstructured":"Khamisi S, Lundqvist M, Emadi P, Almby K, Ljunggren \u00d6, Karlsson FA (2021) Serum thyroglobulin is associated with orbitopathy in Graves\u2019 disease. J Endocrinol Invest 44:1905\u20131911","journal-title":"J Endocrinol Invest"},{"key":"437_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1365-2265.2004.02033.x","volume":"60","author":"SY Goh","year":"2004","unstructured":"Goh SY, Ho SC, Seah LL, Fong KS, Khoo DH (2004) Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves\u2019 disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol (Oxf) 60:600\u2013607","journal-title":"Clin Endocrinol (Oxf)"},{"key":"437_CR24","first-page":"105","volume":"40","author":"K Wojciechowska-Durczynska","year":"2019","unstructured":"Wojciechowska-Durczynska K, Zygmunt A, Matusiak A, Karbownik-Lewinska M, Lewinski A (2019) Positive TgAbs in patients with Graves\u2019 orbitopathy are associated with lower risk of its active form - preliminary study. Neuro Endocrinol Lett 40:105\u2013110","journal-title":"Neuro Endocrinol Lett"},{"key":"437_CR25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2265.2004.02143.x","volume":"61","author":"AK Eckstein","year":"2004","unstructured":"Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K et al (2004) Clinical results of anti-inflammatory therapy in Graves\u2019 ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 61:612\u2013618","journal-title":"Clin Endocrinol (Oxf)"},{"key":"437_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF03348703","volume":"15","author":"N Bromberg","year":"1992","unstructured":"Bromberg N, Romaldini JH, Werner RS, Sgarbi JA, Werner MC (1992) The evolution of Graves\u2019 ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine. J Endocrinol Invest 15:191\u2013195","journal-title":"J Endocrinol Invest"},{"key":"437_CR27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1089\/thy.1999.9.1175","volume":"9","author":"DH Khoo","year":"1999","unstructured":"Khoo DH, Ho SC, Seah LL, Fong KS, Tai ES, Chee SP et al (1999) The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves\u2019 disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9:1175\u20131180","journal-title":"Thyroid"},{"key":"437_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0033-1363193","volume":"122","author":"M Lantz","year":"2014","unstructured":"Lantz M, Planck T, Asman P, Hallengren B (2014) Increased TRAb and\/or low anti-TPO titers at diagnosis of Graves\u2019 disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 122:113\u2013117","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"437_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12519-014-0476-y","volume":"10","author":"JH Lee","year":"2014","unstructured":"Lee JH, Park SH, Koh DG, Suh BK (2014) Thyroid peroxidase antibody positivity and triiodothyronine levels are associated with pediatric Graves\u2019 ophthalmopathy. World J Pediatr 10:155\u2013159","journal-title":"World J Pediatr"},{"key":"437_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2169\/internalmedicine.55.6095","volume":"55","author":"M Katahira","year":"2016","unstructured":"Katahira M, Ogata H (2016) Thyroglobulin Autoantibodies Are Associated with Refractoriness to Antithyroid Drug Treatment for Graves\u2019 Disease. Intern Med 55:1519\u20131524","journal-title":"Intern Med"},{"key":"437_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1210\/jcem-68-6-1097","volume":"68","author":"Y Takaichi","year":"1989","unstructured":"Takaichi Y, Tamai H, Honda K, Nagai K, Kuma K, Nakagawa T (1989) The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves\u2019 disease treated with antithyroidal drugs. J Clin Endocrinol Metab 68:1097\u20131100","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/eje.1.02295","volume":"155","author":"P Laurberg","year":"2006","unstructured":"Laurberg P (2006) Remission of Graves\u2019 disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 155:783\u2013786","journal-title":"Eur J Endocrinol"},{"key":"437_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/thy.1994.4.145","volume":"4","author":"AP Weetman","year":"1994","unstructured":"Weetman AP (1994) The immunomodulatory effects of antithyroid drugs. Thyroid 4:145\u2013146","journal-title":"Thyroid"},{"key":"437_CR34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-2265.1997.d01-2613.x","volume":"46","author":"N Un\u00fcvar","year":"1997","unstructured":"Un\u00fcvar N, Serter R, Aral Y (1997) The effects of smoking on remission and relapse of Graves\u2019 disease. Clin Endocrinol (Oxf) 46:377\u2013378","journal-title":"Clin Endocrinol (Oxf)"},{"key":"437_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/eje.0.1470583","volume":"147","author":"BG Nedrebo","year":"2002","unstructured":"Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE et al (2002) Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves\u2019 disease. Eur J Endocrinol 147:583\u2013589","journal-title":"Eur J Endocrinol"},{"key":"437_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12020-018-1785-z","volume":"63","author":"RV Garc\u00eda-Mayor","year":"2019","unstructured":"Garc\u00eda-Mayor RV, \u00c1lvarez-V\u00e1zquez P, Fluiters E, Valverde D, Andrade A (2019) Long-term remission following antithyroid drug withdrawal in patients with Graves\u2019 hyperthyroidism: parameters with prognostic value. Endocrine 63:316\u2013322","journal-title":"Endocrine"},{"key":"437_CR37","doi-asserted-by":"publisher","first-page":"4853905","DOI":"10.1155\/2017\/4853905","volume":"2017","author":"J Jankauskiene","year":"2017","unstructured":"Jankauskiene J, Jarusaitiene D (2017) The Influence of Juvenile Graves\u2019 Ophthalmopathy on Graves\u2019 Disease Course. J Ophthalmol 2017:4853905","journal-title":"J Ophthalmol"},{"key":"437_CR38","first-page":"195","volume":"49","author":"F Eliana","year":"2017","unstructured":"Eliana F, Suwondo P, Asmarinah A, Harahap A, Djauzi S, Prihartono J et al (2017) The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease. Acta Med Indones 49:195\u2013204","journal-title":"Acta Med Indones"},{"key":"437_CR39","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3892\/etm.2016.3058","volume":"11","author":"L Liu","year":"2016","unstructured":"Liu L, Lu H, Liu Y, Liu C, Xun C (2016) Predicting relapse of Graves\u2019 disease following treatment with antithyroid drugs. Exp Ther Med 11:1453\u20131458","journal-title":"Exp Ther Med"},{"key":"437_CR40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","volume":"44","author":"P Anagnostis","year":"2013","unstructured":"Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C et al (2013) Predictors of long-term remission in patients with Graves\u2019 disease: a single center experience. Endocrine 44:448\u2013453","journal-title":"Endocrine"},{"key":"437_CR41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02933.x","volume":"67","author":"AK Eckstein","year":"2007","unstructured":"Eckstein AK, Lax H, L\u00f6sch C, Glowacka D, Plicht M, Mann K et al (2007) Patients with severe Graves\u2019 ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67:607\u2013612","journal-title":"Clin Endocrinol (Oxf)"},{"key":"437_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2265.1983.tb00577.x","volume":"18","author":"V Stenszky","year":"1983","unstructured":"Stenszky V, Bal\u00e1zs C, Kozma L, Rochlitz S, Bear JC, Farid NR (1983) Identification of subsets of patients with Graves\u2019 disease by cluster analysis. Clin Endocrinol (Oxf) 18:335\u2013345","journal-title":"Clin Endocrinol (Oxf)"},{"key":"437_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fendo.2020.00367","volume":"11","author":"R Le Moli","year":"2020","unstructured":"Le Moli R, Malandrino P, Russo M, Lo Giudice F, Frasca F, Belfiore A et al (2020) Corticosteroid Pulse Therapy for Graves\u2019 Ophthalmopathy Reduces the Relapse Rate of Graves\u2019 Hyperthyroidism. Front Endocrinol (Lausanne) 11:367","journal-title":"Front Endocrinol (Lausanne)"},{"key":"437_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF03350476","volume":"5","author":"C Marcocci","year":"1982","unstructured":"Marcocci C, Chiovato L, Mariotti S, Pinchera A (1982) Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves\u2019 disease. J Endocrinol Invest 5:13\u201319","journal-title":"J Endocrinol Invest"},{"key":"437_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1210\/jcem-61-1-12","volume":"61","author":"L Chiovato","year":"1985","unstructured":"Chiovato L, Vitti P, Lombardi A, Kohn LD, Pinchera A (1985) Expression of the microsomal antigen on the surface of continuously cultured rat thyroid cells is modulated by thyrotropin. J Clin Endocrinol Metab 61:12\u201316","journal-title":"J Clin Endocrinol Metab"},{"key":"437_CR46","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3803\/EnM.2019.34.3.268","volume":"34","author":"YM Choi","year":"2019","unstructured":"Choi YM, Kwak MK, Hong SM, Hong EG (2019) Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves\u2019 Disease Relapse after Antithyroid Drug Therapy. Endocrinol Metab (Seoul) 34:268\u2013274","journal-title":"Endocrinol Metab (Seoul)"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-023-00437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-023-00437-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-023-00437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T12:45:40Z","timestamp":1701953140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-023-00437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s42000-023-00437-7","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Aichi Prefectural University and Ichinomiya Municipal Hospital and was conducted in accordance with the Declaration of Helsinki.<b>Consent to participate<\/b>Informed consent was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}